Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- MHLW Council Approves Subsidizing Telaprevir Combination Therapy
November 24, 2011
- DPJ WT to Propose New Measures to Promote Generics
November 24, 2011
- Committee on OTC Drugs Recommends SSP’s Vaginal Candidiasis Treatment for Approval
November 24, 2011
- Korosho Issues Notification to Ensure Stable Supplies of Flu Drugs This Season
November 24, 2011
- Korosho’s Council Approves Subsidizing 3-Drug Combination Therapy Including Teraprevir
November 22, 2011
- MHLW Study Group Postpones Decision on Relief System for Victims of Health Damages Due to Anticancer Drugs
November 21, 2011
- After Delay, CSIMC Recommends Listing of Ilaris for Treatment of CAPS
November 21, 2011
- US FDA Revokes Avastin’s Approval for Metastatic Breast Cancer
November 21, 2011
- Former Chuikyo Chairman Prof. Endo Concerned about Increasing Drug Expenditure
November 21, 2011
- CSIMC Subcommittee Approves Special Price Reductions for Combination Drugs
November 18, 2011
- CSIMC Excludes DPC Flat-Sum Reimbursement, Recommends Approval for Reimbursement by Piecework for 5 APIs
November 18, 2011
- Korosho Approves 3 Switch OTC Products Containing Pemirolast
November 18, 2011
- Similar Products to Be Re-Priced by Product Following Market Expansion: CSIMC Expert Subcommittee
November 17, 2011
- Industry Renews Call for Perpetual Introduction of Premium for New Drug Development: CSIMC Expert Subcommittee
November 17, 2011
- Re-pricing of Essential Drugs Discussed at CSIMC
November 17, 2011
- CSIMC Recommends Listing of 9 Products Including Imusera; Recommendation Put on Hold for Ilaris
November 17, 2011
- Plaintiffs to Appeal Against “Unprecedented Unjust Ruling”: Iressa Appeal Trial
November 17, 2011
- Subcommittee to Study “Notification System” for Access to Unapproved Drugs
November 17, 2011
- PM Noda Says “Japan Will Not Lose” Public Health Insurance System in TPP
November 16, 2011
- Health Minister Komiyama Says “Government Position Recognized” in Iressa Case
November 16, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…